Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Neoleukin Therapeutics, Inc. | exhibit312.htm |
| EX-31.1 - EX-31.1 - Neoleukin Therapeutics, Inc. | exhibit311.htm |
| EX-10.1 - EX-10.1 - Neoleukin Therapeutics, Inc. | exhibit101.htm |
| 10-Q - 10-Q - Neoleukin Therapeutics, Inc. | nltx-20210331.htm |
Exhibit 32.1
NEOLEUKIN THERAPEUTICS, INC.
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Neoleukin Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Jonathan G. Drachman, President and Chief Executive Officer of the Company, and Robert Ho, Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 12th day of May 2021.
| /s/ Jonathan G. Drachman | /s/ Robert Ho | |||||||
| Jonathan G. Drachman | Robert Ho | |||||||
| President and Chief Executive Officer | Chief Financial Officer | |||||||
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Neoleukin Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.